Virtual Presentation

Myelodysplastic Syndromes

Source: Clinical Issues and Future Directions in Hematologic Malignancies

Myelodysplastic Syndromes


Faculty:

  • Allen S. Yang, MD, PhD

CME CREDIT INFORMATION

Release Date: 04/18/08

Expiration Date: 04/17/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the results of recent studies regarding the use of FDA-approved and investigational agents for the treatment of myelodysplastic syndrome (MDS)
  • Discuss new insights into the etiology and prognostic indicators of MDS
  • Summarize new developments in the management of adverse events related to the treatment of MDS

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.